HCP/Market Conditioning Website (Prostate Cancer)

ABOUT SERA

 

Abbott is researching selective endothelin-A receptor antagonists (SERAs) to determine their potential to change the natural progression of cancer by blocking endothelin-1 (ET-1) from binding to the endothelin-A (ET_A) receptor.

http://www.aboutsera.com/